Which of the following statements regarding tofacitinib is correct? A. It is a new injectable biologic agent indicated for the treatment of rheumatoid arthritis. B. It has a boxed warning for the risk of fetal abnormalities. C. It should be used with a biologic DMARD. D. It is an inhibitor of Janus Kinase enzymes. E. The brand name is Aubagio
